Royalty Pharma

Royalty Pharma

RPRX· Manufacturing· Fiscal year ends in December

CEO pay in FY2025Stock +51.5% in FY2025

Pablo Legorreta is the CEO of Royalty Pharma and was paid $937.5K in FY2025 (Dec).

Pay$100 in the stock at the end of FY24 → $151
CEO pay is from each Royalty Pharma proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Executives5

See all
  1. 1Christopher HiteFY2025
  2. 2George LloydFY2025
  3. 3Marshall Urist, M.D., Ph.D.FY2025
  4. 4Terrance CoyneFY2025
  5. 5Pablo LegorretaFY2025

Named executives and their total pay, from the Summary Compensation Table of the latest proxy.

Pay

See all

Royalty Pharma paid its 5 named executives $6.2M in total in FY2025 (Dec). CEO Pablo Legorreta was paid $937.5K of that.

Name
Christopher HiteExecutive Vice President & Vice Chairman
George LloydSenior Advisor; former Executive Vice President, Chief Legal Officer & Investments
Marshall Urist, M.D., Ph.D.Executive Vice President, Research & Investments
Terrance CoyneExecutive Vice President & Chief Financial Officer
Pablo LegorretaChief Executive OfficerNot disclosedNot disclosed

of each named executive, from the Summary Compensation Table of each proxy.

Peers20

See all

The FY2025 (Dec) proxy of Royalty Pharma names 20 peer companies for pay. Among Royalty Pharma and these peers, CEO pay was the lowest of 9 and total shareholder return was the lowest of 9.

9th highest of 9in Royalty Pharma and its pay peers, FY2025 (Dec) by CEO pay:

$937.5K$68.3M

9th highest of 9in Royalty Pharma and its pay peers, FY2025 (Dec) by total shareholder return:

$85$399

The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year.

Board9

See all
  • Bonnie BasslerDirector · 5 yr on the boardIndependentManagement Development and Compensation—Paid as an executive
  • Catherine EngelbertDirector · 5 yr on the boardIndependentAudit—Paid as an executive
  • Gregory NordenDirector · 5 yr on the boardIndependentAudit (Chair), Nominating and Corporate Governance—Paid as an executive
  • David HodgsonDirector · 3 yr on the boardIndependentAudit, Management Development and Compensation (Chair)—Paid as an executive
  • Carole HoDirector · 0 yr on the boardIndependentNominating and Corporate Governance—Paid as an executive
  • Elizabeth WeathermanDirector · 0 yr on the boardIndependentManagement Development and Compensation—Paid as an executive

The board of the latest proxy (FY2025).

Activity

  1. Pay
    Royalty Pharma CFO pay fell 72% to $1.3M. The stock fell 9% in FY2024 (Dec).
    DEF 14A
  2. Pay
    Royalty Pharma Division head pay fell 72% to $1.3M. The stock fell 9% in FY2024 (Dec).
    DEF 14A
  3. Pay
    Royalty Pharma General counsel pay fell 72% to $1.3M. The stock fell 9% in FY2024 (Dec).
    DEF 14A
  4. Pay
    Royalty Pharma Executive Vice President & Vice Chairman pay fell 72% to $1.3M. The stock fell 9% in FY2024 (Dec).
    DEF 14A
  5. Board
    Vlad Coric, M.D. joined the board of Royalty Pharma. Vlad Coric, M.D. sits on no other public board.
    3
  6. Board
    Elizabeth Weatherman joined the board of Royalty Pharma. Elizabeth Weatherman now sits on 2 public boards.
    3
  7. Board
    Carole Ho joined the board of Royalty Pharma. Carole Ho now sits on 2 public boards.
    3
  8. Pay
    Royalty Pharma CFO pay rose 12% to $4.3M. The stock rose 1% in FY2022 (Dec).
    DEF 14A
  9. Pay
    Royalty Pharma Division head pay rose 23% to $4.3M. The stock rose 1% in FY2022 (Dec).
    DEF 14A
  10. Pay
    Royalty Pharma General counsel pay rose 12% to $4.3M. The stock rose 1% in FY2022 (Dec).
    DEF 14A

Filings5

See all
Proxy statementDEF 14AApr 10, 2026FY2025
Annual report10-KFeb 11, 2026FY2025
Annual report10-KFeb 12, 2025FY2024
Proxy statementDEF 14AApr 25, 2024FY2023
Annual report10-KFeb 15, 2024FY2023
For the press:Download CSVDownload PNGHow to use our data